Sequential Vaccination With 9-Valent HPV Vaccine After Bivalent HPV Vaccine

Randomised, open-label trial of recombinant human papillomavirus 9-valent vaccine in Cervical Cancer (CC) (3 arms), sponsored by Jiangsu Provincial Center for Disease Control and Prevention. Primary endpoints: Geometric mean concentrations of neutralizing antibody levels against HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at 7 months and Incidence of adverse reactions/events within 7 days after each dose of vaccination. Planned start Apr 2026; status: not yet recruiting.